Sorafenib in patients with advanced renal cell carcinoma (RCC) and prior cytokine therapy:: Subgroup analysis of targets

被引：0

作者：

Negrier, S.

Jaeger, E.

Porta, C.

Mc Dermott, D.

Moore, M. S.

Bellmunt, J.

Grimm, MO.

Simantov, R. E.

Anderson, S. S.

Escudier, B.

Bukowski, R.

机构：

[1] Ctr Leon Berard, Dept Med Oncol, F-69373 Lyon, France

[2] Med Klin 2, Krankenhaus Nordwest, Frankfurt, Germany

[3] San Matteo Univ Hosp, IRCCS, Pavia, Italy

[4] Dana Farber Harvard Canc Ctr, Div Hematol Oncol, Boston, MA USA

[5] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada

[6] Hosp Vall d Hebron, PSO Vall d Hebron, Med Oncol Serv, Barcelona, Spain

[7] Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany

[8] Bayer Pharmaceut, Global Prod Dev, West Haven, CT USA

[9] Bayer Pharmaceut, Dept Med Affairs, West Haven, CT USA

[10] Inst Gustave Roussy, Dept Immunothe, Villejuif, France

[11] Cleveland Clin, Ctr Canc, Dept Solid Tumor Oncol, Cleveland, OH USA

来源：

关键词：

D O I：

10.1016/S1569-9056(07)60851-3

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：236 / 236

页数：1